Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Jennerex Presents Positive Clinical Data From Phase II Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients

FDAnews Drug Daily Bulletin

Sept. 18, 2012 | Vol. 9 No. 183

Jennerex Presents Positive Clinical Data From Phase II Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients

Jennerex presented Phase II clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma.
Yahoo! Finance

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Pharma Blog Watch Drug Prices to Increase By 10 Percent Enbrel and the Autoimmune Era India, Argentina Broaden Trade, Co-op Range

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.